# Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia

> **NCT03564678** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 10 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Hyperbilirubinemia

## Interventions

- **DIETARY_SUPPLEMENT:** Levocarnitine
- **DRUG:** Vitamin B Complex

## Key facts

- **NCT ID:** NCT03564678
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-17
- **Primary completion:** 2024-10-15
- **Final completion:** 2024-10-15
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** PI Request. Slow accrual and lack of clinical interest
- **Last updated:** 2025-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03564678

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03564678, "Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT03564678. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*